BioArctic

BioArctic CapEx/OCF

The CapEx to Operating Cash Flow Ratio of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 0.72 %. In the previous year, CapEx to Operating Cash Flow Ratio was -8.42 % — a change of -108.50% (higher).

CapEx/OCF

0.72 %

YoY

-108.50%

Last updated:

CapEx to Operating Cash Flow Ratio of BioArctic is 2025 0.72 % . CapEx to Operating Cash Flow Ratio of BioArctic was 2024 -8.42 % . It decreases by -108.50% higher compared to the previous year.

The BioArctic CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-2.13 SEK
Jan 1, 2019
1.00 SEK
Jan 1, 2020
-13.51 SEK
Jan 1, 2021
-3.12 SEK
Jan 1, 2022
-40.29 SEK
Jan 1, 2023
2.40 SEK
Jan 1, 2024
-8.42 SEK
Jan 1, 2025
0.72 SEK
The BioArctic CapEx/OCF history
YEARCapEx/OCFYoY
0.72 %-108.50%
-8.42 %-450.34%
2.40 %-105.97%
-40.29 %+1,190.15%
-3.12 %-76.88%
-13.51 %-1,454.75%
1.00 %-146.88%
-2.13 %-16.52%
-2.55 %-679.77%
0.44 %-103.15%
-13.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

CapEx to Operating Cash Flow Ratio of BioArctic is 0.72 % in 2025.

CapEx to Operating Cash Flow Ratio of BioArctic changed from -8.42 % to 0.72 %, representing a -108.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio BioArctic since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioArctic

All Key Metrics — BioArctic